financetom
Business
financetom
/
Business
/
Nano Dimension Unveils FOX Ultra & PUMA Ultra For High-Speed Electronics Manufacturing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nano Dimension Unveils FOX Ultra & PUMA Ultra For High-Speed Electronics Manufacturing
Mar 18, 2025 10:26 AM

Nano Dimension Ltd. ( NNDM ) shares are trading lower on Tuesday.

Today, the company announced the launch of its solutions from the Essemtec product line: the FOX Ultra and PUMA Ultra.

These surface mount technology, or SMT, platforms are designed to meet the growing demands of high-precision, high-mix electronics manufacturing.

The FOX Ultra offers a pick-and-place speed of 31,000 components per hour, while the PUMA Ultra reaches 30,000 CPH, marking a 70% increase in throughput.

Both systems are available in an All-in-One version, integrating pick-and-place, dispensing, and inspection capabilities into a single platform.

Also Read: Apple iPhone Shipments In China Drop 21% In January, Goldman Sachs Remains Bullish

According to Olivier Carnal, General Manager for Essemtec at Nano Dimension ( NNDM ), the FOX Ultra and PUMA Ultra systems are designed to meet the needs of industries such as aerospace, defense, medical electronics, and automotive, where speed, flexibility, and precision are crucial.

The PUMA Ultra also offers dual dispensing heads for processes like glue and solder paste jetting.

Julien Lederman, Interim CEO of Nano Dimension ( NNDM ), expressed pride in the new machines, noting that they embody the company's dedication to technological innovation and customer-driven solutions.

According to Benzinga Pro, NNDM stock has lost over 22% in the past year. Investors can gain exposure to the stock via 3D Printing (The) ETF .

Price Action: NNDM shares are trading lower by 2.28% to $2.14 at last check Tuesday.

Read Now:

Chinese Stocks Poised For Best Quarter Vs. S&P 500 Since 2007 As Investors Bet On Policy Turnaround

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Market Chatter: Thai Airways Could Exercise Option to Purchase More Boeing Jets
Market Chatter: Thai Airways Could Exercise Option to Purchase More Boeing Jets
Jul 9, 2025
06:38 AM EDT, 07/09/2025 (MT Newswires) -- Thai Airways International might exercise an option to acquire more Boeing ( BA ) planes as part of the country's tariff discussions with the US, Reuters reported Wednesday, citing Thai Airways Chief Executive Chai Eamsiri. Thai Finance Minister Pichai Chunhavajira recently said the country could purchase more Boeing ( BA ) jets as...
BRIEF-Merck To Acquire Verona Pharma for $10 billion
BRIEF-Merck To Acquire Verona Pharma for $10 billion
Jul 9, 2025
July 9 (Reuters) - Verona Pharma PLC: * MERCK TO ACQUIRE VERONA PHARMA, EXPANDING ITS PORTFOLIO TO INCLUDE OHTUVAYRE® (ENSIFENTRINE), A FIRST-IN-CLASS COPD MAINTENANCE TREATMENT FOR ADULTS AND EXPECTED TO DRIVE GROWTH INTO THE NEXT DECADE * VERONA PHARMA PLC - MERCK TO BUY VERONA PHARMA FOR $10 BILLION * VERONA PHARMA PLC - MERCK TO PAY $107 PER ADS...
Merck to acquire Verona Pharma for $10 billion
Merck to acquire Verona Pharma for $10 billion
Jul 9, 2025
(Reuters) -Merck ( MRK ) will buy UK-based Verona Pharma ( VRNA ) for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of its blockbuster cancer drug. (Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved